Slingshot members are tracking this event:

ZIOPHARM (ZIOP) to complete Phase 1/2 trial of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer by August 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details In December 2015, the Company reported encouraging data, including achievement of the 12 week progression free survival endpoint by the first patient, from a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The study is being conducted at the Memorial Sloan Kettering Cancer Center in New York. A trial in progress poster describing the study was presented at the San Antonio Breast Cancer Symposium in December 2015. The Company expects to present updated data from the study in 2016
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 18, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Single Arm Study, Open-label, Phase 1/2 Trial, Ad-rts-hil-12, Veledimex, Breast Cancer, Metastatic Breast Cancer